EW · 10-Q · 2026Q3 · Full report
Acquisition / Partnership / Divestiture
Edwards Lifesciences Corp · 2026-11-04 · Importance 52 · Surprise 42 · Contradicted
Edwards acquired Autus Valve Technologies in February 2026 for total consideration of $128.9 million, including $35.1 million in cash funded from existing cash. Contingent payments for Autus may reach $132.5 million based on regulatory and sales milestones. Across business acquisition agreements, potential future payments for regulatory, performance, and sales milestones could total $332.5 million at September 30, 2026. Amendments to agreements with the Consolidated VIE in May 2026 made Edwards its primary beneficiary and resulted in consolidation from that date.
Key facts
- At September 30, 2026, potential future payments under Edwards Lifesciences’ business acquisition agreements could total up to $332.5 million upon achievement of regulatory, performance, and sales milestones. source
- In May 2026, amendments to agreements with a medical device company made Edwards Lifesciences the primary beneficiary of the Consolidated VIE, which it consolidated as of May 2026. source
- Edwards Lifesciences acquired Autus Valve Technologies, Inc. in February 2026 for total consideration of $128.9 million, with contingent consideration of up to $132.5 million tied to regulatory and sales milestones. source
- In February 2026, Edwards Lifesciences completed the Autus acquisition for $128.9 million, including $35.1 million cash consideration funded with existing cash. source
- Edwards Lifesciences sold its Critical Care product group to Becton, Dickinson and Company in September 2024. source
- Edwards Lifesciences sold a non-core product group in December 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | +0.9% | In February 2026, Edwards Lifesciences completed the Autus acquisition for $128.9 million, including $35.1 million cash consideration… |
| cash | negative | realized | -0.3% | In February 2026, Edwards Lifesciences completed the Autus acquisition for $128.9 million, including $35.1 million cash consideration… |
| liability | negative | contingent | -0.2% | At September 30, 2026, potential future payments under Edwards Lifesciences’ business acquisition agreements could total up to $332.5… |
| assets | positive | realized | — | Edwards Lifesciences acquired Autus Valve Technologies, Inc. in February 2026 for total consideration of $128.9 million, with contingent… |